As of 2025-06-02, the Intrinsic Value of Tinavi Medical Technologies Co Ltd (688277.SS) is 0.92 CNY. This 688277.SS valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 13.63 CNY, the upside of Tinavi Medical Technologies Co Ltd is -93.30%.
The range of the Intrinsic Value is 0.48 - 1.38 CNY
Based on its market price of 13.63 CNY and our intrinsic valuation, Tinavi Medical Technologies Co Ltd (688277.SS) is overvalued by 93.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (6.10) - (2.77) | (3.77) | -127.7% |
| DCF (Growth 10y) | (2.62) - (5.21) | (3.41) | -125.0% |
| DCF (EBITDA 5y) | 0.48 - 1.38 | 0.92 | -93.3% |
| DCF (EBITDA 10y) | (0.19) - 0.80 | 0.27 | -98.0% |
| Fair Value | -1.37 - -1.37 | -1.37 | -110.07% |
| P/E | (7.56) - (7.57) | (8.20) | -160.2% |
| EV/EBITDA | (4.24) - 1.32 | (2.20) | -116.1% |
| EPV | (5.00) - (6.47) | (5.74) | -142.1% |
| DDM - Stable | (2.45) - (7.23) | (4.84) | -135.5% |
| DDM - Multi | (1.54) - (3.59) | (2.16) | -115.9% |
| Market Cap (mil) | 6,169.89 |
| Beta | 1.87 |
| Outstanding shares (mil) | 452.67 |
| Enterprise Value (mil) | 6,108.45 |
| Market risk premium | 6.13% |
| Cost of Equity | 9.64% |
| Cost of Debt | 5.00% |
| WACC | 9.46% |